|Mr. Anthony P. Mack M.B.A.||Chairman & CEO||375k||N/A||1962|
|Mr. Christopher M. Chipman CPA, CPA||CFO & Corp. Sec.||72k||N/A||1972|
|Dr. Jeffrey A. Gudin M.D.||Exec. VP, Chief Medical Officer & Director||N/A||N/A||1965|
|Dr. Sheila A. Mathias J.D., M.B.A., Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Shana Panzarella||Chief of Staff||N/A||N/A||N/A|
|Mr. Gerald W. Bruce||Exec. VP of Commercial Operations & Director||N/A||N/A||1957|
Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of post-traumatic stress disorder; and MMS019 high-density molecular masking spray to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Virpax Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.